Literature DB >> 10446007

A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis.

P Veras1, C Brodskyn, F Balestieri, L d Freitas, A Ramos, A Queiroz, A Barral, S Beverley, M Barral-Netto.   

Abstract

E10-5A3 is a dhfr-ts- Leishmania major double knockout auxotrophic shown previously to induce substantial protection against virulent L. major infection in both genetically susceptible and resistant mice. We investigated the capacity of dhfr-ts- to protect against heterologous infection by L. amazonensis. The degree of protection was evaluated by immunization of BALB/c or C57BL/6 mice with E10-5A3, followed by L. amazonensis challenge. Whether immunized by subcutaneous (SC) or intravenous (IV) inoculation, susceptible and resistant mice displayed a partial degree of protection against challenge with virulent L. amazonensis. SC-immunized BALB/c mice developed lesions 40 to 65% smaller than non immunized mice, while IV immunization led to protection ranging from 40 to 75% in four out of six experiments compared to non immunized animals. The resistant C57BL/6 mice displayed comparable degrees of protection, 57% by SC and 49% by IV immunization. Results are encouraging as it has been previously difficult to obtain protection by SC vaccination against Leishmania, the preferred route for human immunization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446007     DOI: 10.1590/s0074-02761999000400011

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  18 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

Review 2.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Promotion of a functional B cell germinal center response after Leishmania species co-infection is associated with lesion resolution.

Authors:  Katherine N Gibson-Corley; Paola M Boggiatto; Marie M Bockenstedt; Christine A Petersen; Thomas J Waldschmidt; Douglas E Jones
Journal:  Am J Pathol       Date:  2012-03-17       Impact factor: 4.307

Review 4.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis.

Authors:  Katherine N Gibson-Corley; Paola M Boggiatto; Rami M Mukbel; Christine A Petersen; Douglas E Jones
Journal:  Int J Parasitol       Date:  2009-12-11       Impact factor: 3.981

6.  CD4+ Th1 cells induced by dendritic cell-based immunotherapy in mice chronically infected with Leishmania amazonensis do not promote healing.

Authors:  Yannick F Vanloubbeeck; Amanda E Ramer; Fei Jie; Douglas E Jones
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 7.  Present status of antileishmanial vaccines.

Authors:  Monidipa Ghosh; Santu Bandyopadhyay
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

8.  Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.

Authors:  Cecilia Perez Brandan; Angel M Padilla; Dan Xu; Rick L Tarleton; Miguel A Basombrio
Journal:  PLoS Negl Trop Dis       Date:  2011-12-13

9.  Developments in diagnosis and antileishmanial drugs.

Authors:  Prachi Bhargava; Rajni Singh
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-18

10.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.